ArticleInternational journal of rheumatic diseases2026

Risk Factors for Major Adverse Cardiovascular Events, Malignancies, and Serious Infections With Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of a 3-Year J-Post-Marketing Surveillance.

Kunihiro Yamaoka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.